Generated by All in One SEO v4.9.9, this is an llms.txt file, used by LLMs to index the site.

# Gateway For Cancer Research

## Sitemaps

- [XML Sitemap](https://gatewaycr.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [Home](https://gatewaycr.org/) - Gateway for Cancer Research accelerates practice-changing discoveries in cancer care. Learn more about our mission.
- [Cures Gala](https://gatewaycr.org/curesgala/) - The 35th Annual Cures Gala will be held on October 17, 2026, in Barrington Hills, Illinois. slide 2 Full 1 slide 3 Cures Gala Gallery View photos from the 2025 event by clicking the button below! EVENT PHOTOS
- [Board of Directors](https://gatewaycr.org/about/board-of-directors/) - Board of Directors Providing vision and guidance to Gateway’s mission is a robust group of individuals who have achieved success in their own fields. From banking to research to hospital management to foundations, the Board of Directors help Gateway set strategic priorities that are aligned with a diverse set of patient interests and needs. Richard
- [Share Your Story](https://gatewaycr.org/share/) - We invite you to submit your story and be part of our community. Cancer has impacted everyone in some way and your experience can provide HOPE and healing to those faced with cancer now searching for inspiration from others who understand what they are going through. Whether you are a survivor, family member, caretaker, advocate,
- [Share Your Cancer Survivor Story & Join Us at the Orange Bowl Classic!](https://gatewaycr.org/obshare/) - Are you a cancer survivor? Share your story with Gateway for Cancer Research and score a pair of FREE tickets to the Orange Bowl Classic on December 13, 2025! Fifteen storytellers will also be chosen for our exclusive Tunnel experience, guided by Gateway Ambassador and two-time breast cancer survivor Kristen Berset. If you have any
- [Research FAQs](https://gatewaycr.org/for-researchers/research-faqs/) - Find answers to frequently asked questions regarding Gateway's research process here.
- [Research and Grants Committee](https://gatewaycr.org/about/research-and-grants-committee/) - Research and Grants Committee Gateway for Cancer Research utilizes the expertise of our Research and Grants (Peer Review) Committee to ensure that the organization only funds the most impactful clinical trials. This external body of oncology research experts is comprised of medical oncologists, surgical oncologists, clinician scientists, clinical trialists, naturopathic oncologists, cancer researchers, and patient
- [Gateway Staff](https://gatewaycr.org/about/gateway-staff/) - Gateway's Staff Peter J. Steele Chief Executive Officer Peter J. Steele is a mission-driven executive with a strong record of leading growth, innovation, and organizational impact across enterprise commercial healthcare and national-scale nonprofit sectors. Peter is the kind of leader who doesn’t just talk about HOPE—he’s spent his career building it, one breakthrough at a
- [Pushing Hope](https://gatewaycr.org/pushinghope/) - This tournament isn’t just about raising money. It’s about being part of something bigger. When you participate, you’re helping fund the kind of breakthrough cancer research that could change someone’s life tomorrow. Please join us for the 2026 PUSHING HOPE ANNUAL MARINE INDUSTRY CHARITY TOURNAMENT, where we’re teaming up with an organization that’s changing
- [For Researchers](https://gatewaycr.org/for-researchers/) - Discover Gateway resources for researchers accelerating practice-changing discoveries in cancer care.
- [Gateway Celebrity Fight Night](https://gatewaycr.org/cfngala/) - 2026 Program Book
- [Acknowledged and Supported Publications](https://gatewaycr.org/acknowledged-and-supported-publications/) - Acknowledged and Supported Publications Gruber TA, Jeha S, Deyell RJ, et al. Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study. Lancet Haematol. 2026;S2352-3026(25)00357-6. doi:10.1016/S2352-3026(25)00357-6 Easty D, McDermott R, Murphy AG, et al. Early termination of NCT04617067, a
- [WAYS TO GIVE](https://gatewaycr.org/ways-to-give/) - Support cancer patients and their families by donating to Gateway for Cancer Research. Discover ways to give and make a difference today. Learn more now.
- [Power](https://gatewaycr.org/power/) - Power of the Dollar Did you Know?100% of every dollar donated to Gateway directly funds Phase I and Phase II cancer clinical trials for all types of cancer. The power of the dollar! Richard J Stephenson, founder and chairman of Gateway for Cancer Research, lost his beloved mother to a painful and tragic battle with
- [Privacy Policy](https://gatewaycr.org/privacy-policy-2/) - Privacy Policy Our Commitment to Privacy Gateway for Cancer Research knows that you care how information about you is used and shared, and we appreciate your trust. The information below explains our policy regarding your privacy and the www.gatewaycr.org website. By visiting www.gatewaycr.org, you are accepting the practices described in this Privacy Notice. Our www.gatewaycr.org website is maintained by
- [National Cancer Survivor's Month](https://gatewaycr.org/ncsm/) - National Cancer Survivor’s Month is almost over, but there’s still time to make a difference. Every survivor’s journey is powered by HOPE, determination, and life-changing breakthroughs made possible by your support. For just $34, you can give a patient one more day of treatment, one more chance at a breakthrough, one more reason to HOPE.
- [Newsletter](https://gatewaycr.org/newsletter/) - Monthly Dose of HOPE You’ve just read how your support fuels hope—now help us take the next step. Every story, breakthrough, and life-changing trial featured in our newsletter is made possible by donors like you. Your gift today helps fund bold, patient-focused cancer research with the power to save lives. Join us in moving HOPE
- [The Privacy Policy](https://gatewaycr.org/theprivacypolicy/) - The Privacy Policy The Privacy Policy Effective Date: 1/22/26 Gateway For Cancer Research (“Gateway,” “we,” “our,” or “us”) is committed to protecting your privacy and safeguarding the personal information you share with us. This Privacy Policy describes how we collect, use, protect, and disclose information obtained through our website, communications, programs, events, and services (collectively, the “Services”). By
- [Signature Events](https://gatewaycr.org/ways-to-give/signature-events/) - Signature events raise critical funds to support innovative early-phase research accelerating practice-changing breakthroughs on behalf of all cancer patients.
- [Hope](https://gatewaycr.org/hope24/) - Delivering the healing power of HOPE slide 2 Full 1 slide 3 Donate Today TEXT TO DONATE Text gatewaycr to 41444 Message frequency variesCarries are not liable for delayed or undelivered messagesFor our privacy policy click here
- [Contact Us](https://gatewaycr.org/about/contact-us/) - Contact Us Please provide your contact information so that we can respond to your inquiry. If you would like to contact Gateway by phone, please call: 888-221-2873. Our mailing address is:Gateway for Cancer Research 1449 South Michigan AvenueSuite 13128Chicago, IL 60605 About Board of Directors Gateway Staff Research & Grant Committee In The News Financials Contact
- [Mission Partners](https://gatewaycr.org/about/mission-partners/) - Mission Partners If your organization is looking for a charity partner, Gateway offers a unique opportunity to work with true innovators. Unlike many organizations, 100% of every dollar received by Gateway directly funds cancer clinical trials. With more than 35 years since our inception, Gateway offers stability and a strong reputation among the non-profit community.
- [Giving FAQ](https://gatewaycr.org/ways-to-give/giving-faq/) - Your donations allow us to shape a world in which a cancer diagnosis is no longer feared. Get answers to frequently asked questions about donating to Gateway.
- [Planned Giving](https://gatewaycr.org/ways-to-give/planned-giving/) - There are many charitable planned giving options that will allow Gateway to continue its mission of accelerating practice-changing discoveries in cancer care.
- [Other Ways to Give](https://gatewaycr.org/ways-to-give/other-ways-to-give/) - There are numerous ways that you can fund cancer research and support Gateway’s vision of shaping a world in which a cancer diagnosis is no longer feared.
- [Why Give to Gateway](https://gatewaycr.org/ways-to-give/why-give-to-gateway/) - At Gateway, it is always and only about the patient. Help us fund another day of research, another week or more. Donate to cancer research today!
- [Fundraise for Gateway](https://gatewaycr.org/for-supporters/fundraise-for-gateway/) - Fundraise for Gateway GIVE BACK TO GATEWAY It is only through the support of the community that Gatway is able to continue funding transformational cancer clinical trials. Get Started Thank you for your interest in becoming a fundraiser for Gateway for Cancer Research! We are thrilled that you have chosen our organization to lend your
- [For Supporters](https://gatewaycr.org/for-supporters/) - Join Gateway’s mission to fund breakthrough treatment options for cancer patients that offer real possibilities for feeling and getting better.
- [Financials](https://gatewaycr.org/about/financials/) - Financials Home Financials Annual Reports Gateway funds innovative, early phase clinical research centered on one objective: to end cancer as we know it. We’re driven by passion, a sense of urgency, and a deep desire to have a lasting impact for the patients we are privileged to serve. Within this Annual Report, you’ll learn more
- [Stacie Stephenson](https://gatewaycr.org/about/board-of-directors/stacie-stephenson/) - Dr. Stacie J. Stephenson Vice-Chairman, Gateway for Cancer Research Dr. Stacie J. Stephenson and Mr. Richard J Stephenson have dedicated their lives to creating a better world for future generations. Dr. Stacie J. Stephenson is a doctor, business owner, philanthropist, public speaker, bestselling author, and certified leader in functional and integrative medicine. Recognized for her
- [Richard J Stephenson](https://gatewaycr.org/about/board-of-directors/richard-j-stephenson/) - Richard J Stephenson Founder and Chairman of the Board Philanthropist, entrepreneur and global merchant banker Richard J Stephenson founded Gateway for Cancer Research in 1991, to exclusively fund Phase I and Phase II cancer clinical trials. These trials are crucial to the discovery of innovative new treatments for all types of cancer. However, they are
- [Associates Board](https://gatewaycr.org/about/associates-board/) - Associates Board Founded in 2013, the Associates Board was created to elevate Gateway’s mission and vision among young professionals in the Chicago area and beyond. Its members host fun and exciting events to spotlight Gateway’s groundbreaking work. Members volunteer their time to further Gateway’s reach and impact, participate in activities that increase awareness of Gateway within their
- [About](https://gatewaycr.org/about/) - Gateway for Cancer Research BE A GATEWAY Help Cancer Patients Today Over 10,000 patients have been impacted by Gateway for Cancer Research funded clinical trials to date. Donate Fundraise for Gateway Through our DIY program, GateRaisers, the funds you raise helps us bring cures to people living with all types of cancer. Be a GateRaiser
- [ Making An Impact](https://gatewaycr.org/impact/) - The overall cancer death rate for men, women and children has decreased by 34% since its peak in 1991, the same year Gateway for Cancer Research was established. Blood Cancer Driving advancements in treatment and survival rates. Death Rate Reduction Since 1991, deaths from blood cancer have decreased by 35%. Innovative Clinical Trials Approximately 25%
- [Vino](https://gatewaycr.org/vino/) - Gateway for Cancer Research’s premier Arizona philanthropic event of 2025 Full 1 slide 2 slide 3 slide 3 DONATE TODAY Our Patient Because of your support of Gateway for Cancer Research, Joe had access to a clinical trial that gave him hope when no treatments were available. For him, the decision to participate was an
- [Gateway's Impact](https://gatewaycr.org/for-researchers/gateways-impact/) - Our impact framework is designed to best deliver on our focus of patient-centered therapies and integrative oncology that improves patient’s quality of life.
- [Model of Support](https://gatewaycr.org/for-researchers/model-of-support/) - While helping people live longer is the ultimate goal of most cancer research, we are also re-defining what we mean when we say we're seeking a “cure.”
- [Deliver Hope](https://gatewaycr.org/giving/) - Double your Impact Today Double your Impact Join Shelby & Riley’s $20,000 match and transform lives Cancer touches every family, including ours. By matching year-end gifts up to $20,000, we want to amplify the support that fuels innovative cancer research and gives patients more time, more options, and more HOPE. ABOUT GATEWAY When facing cancer,
- [OBC](https://gatewaycr.org/obc/) - Florida’s sunny climate and coastal lifestyle put residents at greater risk for several cancers, including melanoma (the highest skin cancer risk in the country), lung, breast, colorectal, prostate, and liver cancers. Gateway is driving progress with 17 cutting-edge clinical trials, actively pursuing safer, more effective treatments for these types of cancer. You support provides HOPE
- [mothersday](https://gatewaycr.org/mothersday/) - Gateway for Cancer Research Founder and Chairman, Richard J Stephenson, was inspired to establish the organization in 1991 after losing his mother to cancer. His love for her gave him the strength and desire to find a cure for cancer, a disease that affects so many women and families around the world. Mr. Stephenson and
- [Discovery Grant](https://gatewaycr.org/for-researchers/discovery-grant/) - Discovery Grant A Scientific Partnership with Conquer Cancer, The ASCO Foundation In 2019, Gateway announced a scientific partnership with Conquer Cancer®, the ASCO Foundation, to establish the Gateway Discovery Grant Program. The biennial $1.5 million award supports early phase clinical trials with the greatest potential to advance breakthrough cancer research. The first Gateway Discovery Grant,
- [Attribution](https://gatewaycr.org/attribution/) - Coming soon.

## Clinical Trials

- [HERizon-Breast: A curative-intent ctDNA-guided adaptive study of sequential anti-HER2 therapies and CNS prophylaxis to induce long-term remission in patients with metastatic HER2+ breast cancer](https://gatewaycr.org/for-researchers/clinical-trials/herizon-breast-a-curative-intent-ctdna-guided-adaptive-study-of-sequential-anti-her2-therapies-and-cns-prophylaxis-to-induce-long-term-remission-in-patients-with-metastatic-her2-breast-cancer/) - HERizon-Breast: A curative-intent ctDNA-guided adaptive study of sequential anti-HER2 therapies and CNS prophylaxis to induce long-term remission in patients with metastatic HER2+ breast cancer Summary:Up to 20% of breast cancers are HER2+. Over the past two decades, there has been a tremendous advancement in the treatment of HER2+ breast cancer. It has transformed from the
- [Enasidenib for Patients with Clonal Cytopenias of Undetermined Significance](https://gatewaycr.org/for-researchers/clinical-trials/enasidenib-for-patients-with-clonal-cytopenias-of-undetermined-significance/) - Enasidenib for Patients with Clonal Cytopenias of Undetermined Significance Blood Cancer Washington University in St. Louis Summary Individuals with cytopenia (low blood cell counts) and clonal hematopoiesis (hee-MA-toh-poy-EE-sis), who do not meet the criteria for a hematologic malignancy, have an entity called clonal cytopenias of undetermined significance (CCUS). These patients have an 82% and 95%
- [PEMIGIST: Phase II Study of Pemigatinib in SDH-deficient GIST](https://gatewaycr.org/for-researchers/clinical-trials/pemigist-phase-ii-study-of-pemigatinib-in-sdh-deficient-gist/) - PEMIGIST: Phase II Study of Pemigatinib in SDH-deficient GIST Sarcoma Dana-Farber Cancer Institute Summary Gastrointestinal stromal tumors (GISTs) are a group of rare cancers, with an incidence of 4,000 to 6,000 new cases per year in the United States. Approximately 10-15% of adult GISTs and the majority of pediatric GISTs are driven by the loss
- [Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD](https://gatewaycr.org/for-researchers/clinical-trials/serial-response-and-biomarker-guided-steroid-taper-for-children-with-gvhd/) - Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD Pediatric Blood Cancer John Levine, MD, MS Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute Summary: Allogeneic hematopoietic stem cell transplants (stem cell transplant from a donor) [HSCT] are an important treatment for high-risk hematologic (blood) malignancies. However, these transplants can result in
- [PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC with Residual Disease](https://gatewaycr.org/for-researchers/clinical-trials/predict-rd-postoperative-molecular-residual-disease-by-ctdna-surveillance-in-tnbc-with-residual-disease/) - PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC with Residual Disease Breast Cancer Yara Abdou, MD University of North Carolina Summary: Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of new breast cancer cases and has been associated with poor clinical outcomes. Recently, neoadjuvant chemo-immunotherapy has been established as the standard of care
- [A Phase II Trial of Pembrolizumab + GVD with ctDNA-guided Consolidation in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma](https://gatewaycr.org/for-researchers/clinical-trials/a-phase-ii-trial-of-pembrolizumab-gvd-with-ctdna-guided-consolidation-in-patients-with-relapsed-refractory-classic-hodgkin-lymphoma/) - A Phase II Trial of Pembrolizumab + GVD with ctDNA-guided Consolidation in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Blood Cancer Michael Spinner, MD University of California, San Francisco Summary: The current standard of care for relapsed or refractory classic Hodgkin lymphoma (cHL) is salvage chemotherapy followed by autologous stem cell transplant (ASCT), resulting in a
- [Omission of Surgery after Neoadjuvant Chemotherapy in Breast Cancer](https://gatewaycr.org/for-researchers/clinical-trials/omission-of-surgery-after-neoadjuvant-chemotherapy-in-breast-cancer/) - Omission of Surgery after Neoadjuvant Chemotherapy in Breast Cancer Breast Cancer Sachin Jhawar, MD, MSCI The Ohio State University Summary: There is a potential for a paradigm shift in the way some early-stage breast cancer patients are treated. Currently, every breast cancer patient undergoing curative intent treatment requires surgery. However, for patients that achieved a
- [A Phase II Multi-Center Open-Label Randomized Study of Capecitabine in Combination with Elacestrant versus Capecitabine Alone in Advanced Estrogen Receptor Positive Breast Cancer (CapEla)](https://gatewaycr.org/for-researchers/clinical-trials/a-phase-ii-multi-center-open-label-randomized-study-of-capecitabine-in-combination-with-elacestrant-versus-capecitabine-alone-in-advanced-estrogen-receptor-positive-breast-cancer-capela/) - A Phase II Multi-Center Open-Label Randomized Study of Capecitabine in Combination with Elacestrant versus Capecitabine Alone in Advanced Estrogen Receptor Positive Breast Cancer (CapEla) Breast Cancer Rinath Jeselsohn, MD Dana-Farber Cancer Institute Summary: Endocrine therapy and targeted therapy such as CDK4/6 inhibitors and other inhibitors targeting the PI3K-AKT-mTOR pathway are highly effective in metastatic hormone
- [NANT2101 STING (Sequential Temozolomide, Irinotecan, NK cells, and GD2 mAb)​](https://gatewaycr.org/for-researchers/clinical-trials/nant2101-sting-sequential-temozolomide-irinotecan-nk-cells-and-gd2-mab/) - NANT2101 STING (Sequential Temozolomide, Irinotecan, NK cells, and GD2 mAb)​ Neuroblastoma Araz Marachelian, MD, MS Children's Hospital Los Angeles Summary: Neuroblastoma is the most common cancer diagnosed in infants. The average age of children when they are diagnosed is about 1 to 2 years and about 90% of cases are diagnosed by age 5.​ Historically
- [Phase I Study of EZH2 Inhibitor Tulmimetostat in Cutaneous T-cell Lymphoma](https://gatewaycr.org/for-researchers/clinical-trials/phase-i-study-of-ezh2-inhibitor-tulmimetostat-in-cutaneous-t-cell-lymphoma/) - Phase I Study of EZH2 Inhibitor Tulmimetostat in Cutaneous T-cell Lymphoma Blood Cancer Neha Mehta-Shah, MD, MSCI Summary: Cutaneous T-cell lymphomas (CTCL) are a rare subset of T-cell non-Hodgkin’s lymphomas that are present in the skin but can also involve the lymph nodes and bloodstream. Mycosis fungoides (MF) and its rarer leukemic variant, Sezary syndrome
- [AML23: A Phase 2 study of venetoclax in children with newly diagnosed AML](https://gatewaycr.org/for-researchers/clinical-trials/aml23-a-phase-2-study-of-venetoclax-in-children-with-newly-diagnosed-aml/) - AML23: A Phase 2 study of venetoclax in children with newly diagnosed AML Pediatric Blood Cancer Hiroto Inaba, MD, PhD St. Jude Children's Research Hospital Summary: Although the survival rates for children with acute myeloid leukemia (AML) have reached 70%, little improvement has been made in the past 20 years. Approximately 25% of patients relapse and only about 40% of
- [Phase II telemedicine study of pemigatinib in adult patients with advanced or metastatic pancreas cancer with FGFR2 gene fusions or other FGFR genetic alterations](https://gatewaycr.org/for-researchers/clinical-trials/phase-ii-telemedicine-study-of-pemigatinib-in-adult-patients-with-advanced-or-metastatic-pancreas-cancer-with-fgfr2-gene-fusions-or-other-fgfr-genetic-alterations/) - Phase II telemedicine study of pemigatinib in adult patients with advanced or metastatic pancreas cancer with FGFR2 gene fusions or other FGFR genetic alterations Pancreatic Cancer Sameek Roychowdhury, MD, PhD The Ohio State University Summary: Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. Despite current standard first-line therapy with
- [Telemedicine for FGFR focused diagnostics & novel cholangio therapies](https://gatewaycr.org/for-researchers/clinical-trials/telemedicine-for-fgfr-focused-diagnostics-novel-cholangio-therapies/) - Telemedicine for FGFR focused diagnostics & novel cholangio therapies Liver/Bile Duct Sameek Roychowdhury, MD, PhD The Ohio State University Summary: Cholangiocarcinoma is a rare and aggressive liver cancer affecting the bile duct. Patients with cholangiocarcinoma can benefit from clinical and genetics expertise found at university-based cancer centers. However, most patients cannot travel long distances and
- [Pan-cancer telemedicine registry of immunotherapy responses in patients with structural variations in PD-1 ligands](https://gatewaycr.org/for-researchers/clinical-trials/pan-cancer-telemedicine-registry-of-immunotherapy-responses-in-patients-with-structural-variations-in-pd-1-ligands/) - Pan-cancer telemedicine registry of immunotherapy responses in patients with structural variations in PD-1 ligands All Cancers Sameek Roychowdhury, MD, PhD The Ohio State University Summary: Cancer cells evolve and develop protective mechanisms to hide themselves from cancer killing T-cells. Immune checkpoint inhibitors (ICIs), block these protective mechanisms by targeting PD-1/PD-L1, unhiding cancer cells so that
- [The ARCHER trial (Ablation and Resection for the Consolidation of Oligometastatic HER2+ Breast Cancer)](https://gatewaycr.org/for-researchers/clinical-trials/the-archer-trial-ablation-and-resection-for-the-consolidation-of-oligometastatic-her2-breast-cancer/) - The ARCHER trial (Ablation and Resection for the Consolidation of Oligometastatic HER2+ Breast Cancer) Breast Cancer Lior Braunstein, MD Memorial Sloan Kettering Cancer Center Summary: In recent years, several highly effective targeted agents have emerged for HER2-positive (HER2+) breast cancer, converting a breast cancer subtype that historically had the worst outcomes to the most favorable
- [Predictive biomarkers for pneumonitis after chemoradiotherapy and immunotherapy in Patients With Non-small Cell Lung Cancer](https://gatewaycr.org/for-researchers/clinical-trials/predictive-biomarkers-for-pneumonitis-after-chemoradiotherapy-and-immunotherapy-in-patients-with-non-small-cell-lung-cancer/) - Predictive biomarkers for pneumonitis after chemoradiotherapy and immunotherapy in Patients With Non-small Cell Lung Cancer Lung Cancer Ajay Sheshadri, MD, MSCI MD Anderson Cancer Center Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by producing durable responses. For example, approximately up to 20% of patients with metastatic non-small cell lung cancer (NSCLC) have durable
- [Responder-derived FMT and anti-PD-1 in PD-1 refractory melanoma and NSCLC](https://gatewaycr.org/for-researchers/clinical-trials/responder-derived-fmt-and-anti-pd-1-in-pd-1-refractory-melanoma-and-nsclc/) - Responder-derived FMT and anti-PD-1 in PD-1 refractory melanoma and NSCLC Solid Tumors Diwakar Davar, MD, MSc University of Pittsburgh Summary: Cancer cells evolve and develop protective mechanisms to hide themselves from cancer killing T-cells. Immune checkpoint inhibitors (ICI), block these protective mechanisms by targeting PD-1/PD-L1 (or CTLA-4), unhiding cancer cells so that they can be
- [Phase II study of All-trans retinoic acid and Cemiplimab in Leiomyosarcoma](https://gatewaycr.org/for-researchers/clinical-trials/phase-ii-study-of-all-trans-retinoic-acid-and-cemiplimab-in-leiomyosarcoma/) - Phase II study of All-trans retinoic acid and Cemiplimab in Leiomyosarcoma Sarcoma Gabriel Tinoco, MD The Ohio State University Summary: Soft-tissue sarcomas encompass a group of rare malignant tumors and account for less than 1% of all adult malignancies in the United States. There are an estimated 13,130 new cases per year and approximately 5,350
- [Phase II Trial of Relatlimab plus Nivolumab in Renal Medullary Carcinoma](https://gatewaycr.org/for-researchers/clinical-trials/phase-ii-trial-of-relatlimab-plus-nivolumab-in-renal-medullary-carcinoma/) - Clinical Trial Phase II Trial of Relatlimab plus Nivolumab in Renal Medullary Carcinoma Kidney Cancer Pavlos Msaouel, MD PhD MD Anderson Cancer Center Summary: Renal medullary carcinoma (RMC) is a rare kidney cancer that predominately affects those of African descent carrying the sickle cell trait. Additionally, it is one of the most aggressive kidney cancers
- [Azacitidine, Venetoclax and NK Cells in Newly Daignosed Older/Unfit AML](https://gatewaycr.org/for-researchers/clinical-trials/azacitidine-venetoclax-and-nk-cells-in-newly-daignosed-older-unfit-aml/) - Azacitidine, Venetoclax and NK Cells in Newly Diagnosed Older/Unfit AML Blood Cancer Abhishek Maiti, MD MD Anderson Cancer Center Summary: Older patients with adverse-risk acute myeloid leukemia (AML) have dismal outcomes with a 3-year survival of roughly 20%. Fifty to 60% of newly diagnosed older patients with AML do not respond to current standard frontline
- [Phase II Clinical Trial of FOLFOX, Botensilimab, Plus Balstilimab in Patients with Localized Rectal Cancer](https://gatewaycr.org/for-researchers/clinical-trials/phase-ii-clinical-trial-of-folfox-botensilimab-plus-balstilimab-in-patients-with-localized-rectal-cancer/) - Phase II Clinical Trial of FOLFOX, Botensilimab, Plus Balstilimab in Patients with Localized Rectal Cancer Colorectal Cancer Marwan Fakih, MD City of Hope Summary: In recent years, there has been an increased focus on non-operative management in patients with rectal cancer experiencing complete responses with total neoadjuvant therapy. ​However, despite aggressive approaches, only 50% of
- [Protein Pathway Activation Profiling of the ISPY-2 Trial](https://gatewaycr.org/for-researchers/clinical-trials/protein-pathway-activation-profiling-of-the-ispy-2-trial/) - Protein Pathway Activation Profiling of the ISPY-2 Trial Breast Cancer Emanuel Petricoin, PhD George Mason University Summary: For women with newly diagnosed Stage II/III breast cancer, achieving a complete pathological response in the neoadjuvant setting is one of the single most important therapeutic outcomes that can be obtained. Patients who achieve it have 7 to
- [The STOP-HER2 Study](https://gatewaycr.org/for-researchers/clinical-trials/the-stop-her2-study/) - The STOP-HER2 Study Breast Cancer Heather Parsons, MD, MPH Dana-Farber Cancer Institute Summary: HER2 positive (HER2+) breast cancers account for 20-25% of breast cancers and are associated with higher rates of recurrence and brain metastases. However, in the past two decades, HER2 targeting therapies have drastically improved patient outcomes and most patients treated with stage
- [Targeted Therapy Combined with Pembrolizumab in Anaplastic Thyroid Cancer: Two Phase II Clinical Trials](https://gatewaycr.org/for-researchers/clinical-trials/targeted-therapy-combined-with-pembrolizumab-in-anaplastic-thyroid-cancer-two-phase-ii-clinical-trials/) - Targeted Therapy Combined with Pembrolizumab in Anaplastic Thyroid Cancer: Two Phase II Clinical Trials Thyroid Cancer Mark Zafereo, MD, FACS MD Anderson Cancer Center Summary: Anaplastic thyroid cancer (ATC) is a rare thyroid cancer representing less than 2% of all thyroid cancers. However, it is one of the most lethal human malignancies with a historical
- [RMC-5552 in Adults with Recurrent Glioblastoma](https://gatewaycr.org/for-researchers/clinical-trials/rmc-5552-in-adults-with-recurrent-glioblastoma/) - RMC-5552 in Adults with Recurrent Glioblastoma Brain Cancer Nicholas Butowski, MD University of California, San Francisco Summary: Despite current treatment with surgery, radiation, and chemotherapy, glioblastoma (GBM) will inevitably recur within 6 to 13 months of treatment. The median survival from recurrence is approximately 9 months. ​Furthermore, there is no standardized established therapy for progressive
- [Psilocybin-Assisted Psychotherapy in Patients with Advanced Cancer on Maintenance Therapy Experiencing Depression and/or Anxiety](https://gatewaycr.org/for-researchers/clinical-trials/psilocybin-assisted-psychotherapy-in-patients-with-advanced-cancer-on-maintenance-therapy-experiencing-depression-and-or-anxiety/) - Psilocybin-Assisted Psychotherapy in Patients with Advanced Cancer on Maintenance Therapy Experiencing Depression and/or Anxiety Solid Tumors Moran Amit, MD, PhD MD Anderson Cancer Center Summary: Advances in systemic treatments like immunotherapy and targeted therapies have changed the way we think about cancer. A cancer diagnosis is no longer just a question of cure or death;
- [Prebiotic fibre supplementation during haematological cancer treatment](https://gatewaycr.org/for-researchers/clinical-trials/prebiotic-fibre-supplementation-during-haematological-cancer-treatment/) - Prebiotic fibre supplementation during haematological cancer treatment Blood Cancer Sarah Andersen, PhD, ADV APD Royal Brisbane and Women's Hospital Summary: Research indicates that the diversity of bacteria in the gastrointestinal tract decreases rapidly during initial leukemia treatment and remains low through stem cell transplantation. ​Low GI microbiome diversity is associated with more infections and higher
- [Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With Brain metastasis of TNBC, NSCLC, and Other Tumor Types](https://gatewaycr.org/for-researchers/clinical-trials/phase-ii-study-of-pembrolizumab-in-combination-with-lenvatinib-in-patients-with-brain-metastasis-of-tnbc-nsclc-and-other-tumor-types/) - Clinical TrialPhase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With Brain metastasis of TNBC, NSCLC, and Other Tumor Types Solid Tumors Jordi Rodon, MD, PhD MD Anderson Cancer Center Summary: Approximately 200,00 patients are diagnosed with brain metastasis in the United States annually, comprising about 10% of all cancer patients. Furthermore, approximately
- [Phase I/II Study of Pamiparib (BGB-290) with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations](https://gatewaycr.org/for-researchers/clinical-trials/phase-i-ii-study-of-pamiparib-bgb-290-with-temozolomide-in-recurrent-gliomas-with-idh1-2-mutations/) - Phase I/II Study of Pamiparib (BGB-290) with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations Brain Cancer Ranjit Bindra, MD, PhD Yale University Summary: IDH1/2 mutations are commonly found in adult gliomas. Gliomas with these mutations are thought to have a better prognosis than patients without the IDH1/2 mutations, but nearly all patients will eventually recur,
- [Phase 2 study of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-negative cancers](https://gatewaycr.org/for-researchers/clinical-trials/novel-use-of-nivolumab-in-combination-with-ipilimumab-in-pediatric-patients-with-relapse-or-refractory-ini1-negative-cancers/) - Phase 2 study of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-negative cancers Pediatric Rare Cancer Suzanne Forrest, MD Dana-Farber Cancer Institute Summary: INI1 is a tumor suppressor gene and several aggressive pediatric tumor types are characterized by INI1 negativity, including rhabdoid tumors, epithelioid sarcoma, and chordoma. These cancers represent
- [Phase 1 trial of CD40 agonist, Flt3L, and chemotherapy in breast cancer](https://gatewaycr.org/for-researchers/clinical-trials/phase-1-trial-of-cd40-agonist-flt3l-and-chemotherapy-in-breast-cancer/) - Phase 1 trial of CD40 agonist, Flt3L, and chemotherapy in breast cancer Breast Cancer Sangeetha Reddy, MD, MSCI University of Texas Southwestern Medical Center Summary: Triple negative breast cancer (TNBC) is associated with more aggressive disease compared to other subtypes of breast cancer, with a median survival of less than 18 months for a patient
- [Personalized Neoantigen Vaccine and Durvalumab in ES-SCLC](https://gatewaycr.org/for-researchers/clinical-trials/personalized-neoantigen-vaccine-and-durvalumab-in-es-sclc/) - Personalized Neoantigen Vaccine and Durvalumab in ES-SCLC Lung Cancer Jeffrey Ward, MD, PhD Washington University in St. Louis Summary: Small cell lung cancer (SCLC) is an aggressive type of lung cancer that accounts for up to 15% of all new diagnoses of lung cancers. Each year, over 30,000 new patients will be diagnosed with SCLC
- [Pedi-cRIB: Overlapping Immunotherapy and Chemotherapy for Relapsed Leukemia](https://gatewaycr.org/for-researchers/clinical-trials/pedi-crib-overlapping-immunotherapy-and-chemotherapy-for-relapsed-leukemia/) - Pedi-cRIB: Overlapping Immunotherapy and Chemotherapy for Relapsed Leukemia Pediatric Blood Cancer David McCall, MD MD Anderson Cancer Center Summary: Despite notable advances in bringing immunotherapy to pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL), the most commonly used treatment regimen for relapsed disease (ALLR3) still results in the death of 2% of patients and a severe infection
- [PARPAML: A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination with Chemotherapy](https://gatewaycr.org/for-researchers/clinical-trials/parpaml-a-phase-i-protocol-for-relapsed-pediatric-aml-to-determine-the-safety-and-efficacy-of-the-parp-inhibitor-talazoparib-in-combination-with-chemotherapy/) - PARPAML: A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination with Chemotherapy Pediatric Blood Cancer Jennifer Kamens, MD Stanford University Summary: Currently, the survival of children diagnosed with AML sits at less than 70%. Despite 80 to 90% of patients achieving first complete
- [OPTIMIZE A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation](https://gatewaycr.org/for-researchers/clinical-trials/optimize-a-phase-ii-study-of-reduced-dose-post-transplantation-cyclophosphamide-as-gvhd-prophylaxis-in-adult-patients-with-hematologic-malignancies-receiving-hla-mismatched-unrelated-donor-peripheral/) - OPTIMIZE A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation Blood Cancer Jeffery Auletta, MD NMDP/Be The Match Summary: Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for many hematologic disorders. ​The best outcomes
- [A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer with expansion cohort in PD-L1 negative TNBC](https://gatewaycr.org/for-researchers/clinical-trials/a-phase-i-ii-study-evaluating-the-safety-and-efficacy-of-ivermectin-in-combination-with-balstilimab-in-patients-with-metastatic-triple-negative-breast-cancer-with-expansion-cohort-in-pd-l1-negative-tn/) - A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer with expansion cohort in PD-L1 negative TNBC Breast Cancer Yuan Yuan, MD, PhD Cedars-Sinai Medical Center Summary: Triple negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and it is
- [Neoadjuvant Futibatinib plus Durvalumab in Muscle Invasive Bladder Cancer](https://gatewaycr.org/for-researchers/clinical-trials/neoadjuvant-futibatinib-plus-durvalumab-in-muscle-invasive-bladder-cancer/) - Neoadjuvant Futibatinib plus Durvalumab in Muscle Invasive Bladder Cancer Bladder Cancer Yuanquan Yang, MD, PhD The Ohio State University Summary: Bladder cancer is the 6th most common cancer in the US with about 81,000 new cases annually. Approximately 30% of patients present with muscle-invasive bladder cancer (MIBC) and these patients have an increased risk of
- [Enhancing the metabolic function of CAR T cells for lymphoma](https://gatewaycr.org/for-researchers/clinical-trials/enhancing-the-metabolic-function-of-car-t-cells-for-lymphoma/) - Enhancing the metabolic function of CAR T cells for lymphoma Blood Cancer Gunjan Shah, MD Memorial Sloan Kettering Cancer Center Summary: CAR T-cell therapy has changed the treatment paradigms of relapsed diffuse large B-cell lymphoma (DLBCL) by demonstrating long term durability in approximately 40% of treated patients. CAR T-cell therapy is when a patient’s own
- [Enhancing Inclusivity: Community-Focused Decentralization Of Avapritinib Phase 2 Basket Study For Improved Access And Community Engagement​](https://gatewaycr.org/for-researchers/clinical-trials/enhancing-inclusivity-community-focused-decentralization-of-avapritinib-phase-2-basket-study-for-improved-access-and-community-engagement/) - Enhancing Inclusivity: Community-Focused Decentralization Of Avapritinib Phase 2 Basket Study For Improved Access And Community Engagement​ Solid Tumors Blessie Elizabeth Nelson, MD, DMRT MD Anderson Cancer Center Summary: Randomized clinical trials are the gold standard for clinical research and remain the most robust method for assessing the efficacy and safety of new therapeutic interventions. ​However,
- [Copper depletion as a therapeutic strategy to prevent metastases in triple negative breast cancer: Unraveling the mechanisms behind the effect of copper depletion on the tumor and tumor microenvironment](https://gatewaycr.org/for-researchers/clinical-trials/copper-depletion-as-a-therapeutic-strategy-to-prevent-metastases-in-triple-negative-breast-cancer-unraveling-the-mechanisms-behind-the-effect-of-copper-depletion-on-the-tumor-and-tumor-microenvironmen/) - Copper depletion as a therapeutic strategy to prevent metastases in triple negative breast cancer: Unraveling the mechanisms behind the effect of copper depletion on the tumor and tumor microenvironment Breast Cancer Linda Vahdat, MD, MBA Dartmouth Summary: Triple-negative breast cancer (TNBC) is an aggressive cancer that accounts for 15-20% of all breast cancer cases; however,
- [Clinical Trial of Androgen Deprivation Therapy and Copanlisib in High-Risk Prostate Cancer Patients with PTEN Loss Prior to Radical Prostatectomy](https://gatewaycr.org/for-researchers/clinical-trials/clinical-trial-of-androgen-deprivation-therapy-and-copanlisib-in-high-risk-prostate-cancer-patients-with-pten-loss-prior-to-radical-prostatectomy/) - Clinical Trial of Androgen Deprivation Therapy and Copanlisib in High-Risk Prostate Cancer Patients with PTEN Loss Prior to Radical Prostatectomy Prostate Cancer Dana Rathkopf, MD Memorial Sloan Kettering Cancer Center Summary: Prostate cancer is the most common cancer in men and is the second leading cause of cancer death in men. It is characterized by
- [Botensilimab and Balstilimab Optimization in Colorectal cancer (BB-OPCO)](https://gatewaycr.org/for-researchers/clinical-trials/botensilimab-and-balstilimab-optimization-in-colorectal-cancer-bb-opco/) - Botensilimab and Balstilimab Optimization in Colorectal cancer (BB-OPCO) Colorectal Cancer Nicholas DeVito, MD Duke University Summary: Eighty-five percent of colorectal cancer (CRC) are Microsatellite stable (MSS). MSS CRC has had limited response to conventional immune checkpoint inhibitors (ICIs), especially those with liver metastasis. ICIs work by blocking cancer cells’ ability to hide themselves from cancer
- [A randomized phase 2 study of local ablation with stereotactic body radiotherapy (SBRT) for patients with oligometastatic adenoid cystic carcinoma (ACC)](https://gatewaycr.org/for-researchers/clinical-trials/a-randomized-phase-2-study-of-local-ablation-with-stereotactic-body-radiotherapy-sbrt-for-patients-with-oligometastatic-adenoid-cystic-carcinoma-acc/) - A randomized phase 2 study of local ablation with stereotactic body radiotherapy (SBRT) for patients with oligometastatic adenoid cystic carcinoma (ACC) Head/Neck Cancer Jonathan Schoenfeld, MD, MPhil, MPH Dana-Farber Cancer Institute Summary: Adenoid cystic carcinoma (ACC) is a rare type of salivary gland tumor. Despite upfront aggressive treatment with surgery, radiation therapy, and/or chemotherapy, approximately
- [A phase II trial of defactinib and VS-6766 in diffuse gastric cancer](https://gatewaycr.org/for-researchers/clinical-trials/a-phase-ii-trial-of-defactinib-and-vs-6766-in-diffuse-gastric-cancer/) - A phase II trial of defactinib and VS-6766 in diffuse gastric cancer Stomach Cancer Ryan Moy, MD, PhD Columbia University Summary: Globally there are over 1 million cases and nearly 780,000 deaths from gastric cancer each year. ​The long-term survival rates for patients with advanced disease remain abysmal with less than 5% alive at 5-year
- [A Phase I Study of Venetoclax in Combination with Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults with High-Risk Hematologic Malignancies](https://gatewaycr.org/for-researchers/clinical-trials/a-phase-i-study-of-venetoclax-in-combination-with-cytotoxic-chemotherapy-including-calaspargase-pegol-for-children-adolescents-and-young-adults-with-high-risk-hematologic-malignancies/) - A Phase I Study of Venetoclax in Combination with Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults with High-Risk Hematologic Malignancies Pediatric Blood Cancer Andrew Place, MD, PhD Dana-Farber Cancer Institute Summary: Effective treatment for children and young adults with relapsed/refractory MDS, MDS-associated AML (MDS/AML), treatment related MDS/AML, and relapsed/refractory high-risk ALL/LBL
- [A Phase 1b/2 Trial of Immunotherapy with Avelumab and Pepinemab as Second Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma](https://gatewaycr.org/for-researchers/clinical-trials/a-phase-1b-2-trial-of-immunotherapy-with-avelumab-and-pepinemab-as-second-line-treatment-for-patients-with-metastatic-pancreatic-adenocarcinoma/) - A Phase 1b/2 Trial of Immunotherapy with Avelumab and Pepinemab as Second Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma Pancreatic Cancer David Linehan, MD University of Rochester Summary: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers and an almost uniformly fatal malignancy. Treatment outcomes remain dismal with a 5-year survival of

## Press Releases

- [The Benefits of a Cancer Screening](https://gatewaycr.org/about/in-the-news/cancer-screening/) - A screening test can detect cancer while it’s still in its early stages, making treatment easier and more effective. Learn whether a screening is right for you.
- [Gateway for Cancer Research, Ohio State University Pancreas Cancer Trial Expanding](https://gatewaycr.org/about/in-the-news/gateway-for-cancer-research-ohio-state-university-pancreas-cancer-trial-expanding/) - Gateway for Cancer Research, Ohio State University Pancreas Cancer Trial Expanding By Administrator Media Contact: Megan Foellmfoell@kruppagency.com(203) 516-1694 Study results spur drug manufacturer to fund trial expansion for rare pancreas cancer CHICAGO (June 8, 2023) – Gateway for Cancer Research, a nonprofit organization dedicated to funding transformational early phase cancer clinical trials around the
- [Gateway for Cancer Research Announces Leadership Transition, Positioning Organization for Its Next Chapter of Growth](https://gatewaycr.org/about/in-the-news/gateway-for-cancer-research-announces-leadership-transition-positioning-organization-for-its-next-chapter-of-growth/) - New Leadership Underscores Organization's Commitment to Advancing Early-Phase Clinical Trials and Accelerating Breakthroughs for Cancer Patients Worldwide Mr. Richard J Stephenson and Dr. Stacie J. Stephenson, Chairman and Vice-Chair of Gateway for Cancer Research, a nonprofit 501(c)(3) organization dedicated exclusively to funding innovative early Phase I and Phase II cancer clinical trials, today announced a
- [A Guide to Cancer Staging](https://gatewaycr.org/about/in-the-news/cancer-stages/) - Cancer staging is a process that determines how far cancer has spread in your body. Learn about the four cancer stages and how they affect your treatment plan.
- [Cancer Treatment Options](https://gatewaycr.org/about/in-the-news/cancer-treatment/) - There’s no cure for cancer, but there are many effective treatments. Your treatment options depend on the type of cancer you have and how far it has spread.
- [Cancer Prevention: 10 Ways to Reduce Cancer Risk](https://gatewaycr.org/about/in-the-news/cancer-prevention/) - Currently there is no surefire way to prevent cancer, but there are many things you can do to reduce your cancer risk. Learn 10 ways you can reduce your risk.
- [What is Cancer? Understanding the Disease and its Causes](https://gatewaycr.org/about/in-the-news/what-is-cancer/) - Cancer is a range of diseases in which abnormal cells grow rapidly, and in some cases invade other parts of the body. Learn how cancer works and what causes it.
- [What Causes Cancer? 10 Common Factors](https://gatewaycr.org/about/in-the-news/cancer-causes/) - Learn about the most common factors that contribute to the development of cancer so you can live a healthy lifestyle and reduce your cancer risk.
- [Cancer & Post-Traumatic Stress Disorder (PTSD)](https://gatewaycr.org/about/in-the-news/1-in-5-cancer-survivors-live-with-post-traumatic-stress-disorder-ptsd/) - Learn how a cancer diagnosis can lead to PTSD, explore coping strategies, and find support to navigate the emotional impact of Cancer and PTSD.
- [Brain Cancer Surpasses Leukemia as Deadliest Childhood Cancer](https://gatewaycr.org/about/in-the-news/brain-cancer-surpasses-leukemia-as-deadliest-childhood-cancer/) - Brain cancer is now the deadliest form of childhood cancer, surpassing Leukemia. Learn about how brain cancer has remained challenging to treat.
- [Understanding Different Types of Cancer](https://gatewaycr.org/about/in-the-news/types-of-cancer/) - Explore the diverse types of cancer from Carcinoma to Brain and Spinal Cord Cancers. Discover insights on Sarcoma, Leukaemia, Lymphoma, and Myeloma at GatewayCR
- [Signs and Symptoms of Cancer](https://gatewaycr.org/about/in-the-news/cancer-symptoms/) - Recognizing cancer symptoms may help you catch the disease in its early stages. Learn which symptoms to look out for, and what to do if you have symptoms.
- [Personalizing the fight against small cell lung cancer](https://gatewaycr.org/about/in-the-news/personalizing-the-fight-against-small-cell-lung-cancer/) - Personalizing the fight against small cell lung cancer Small cell lung cancer (SCLC) is a tough and fast-moving kind of lung cancer. Even with chemo, most patients see their cancer come back quickly, and there haven’t been many big breakthroughs in treatment for years. Now, a new clinical trial is trying something different: personalizing the
- [Helping patients with lung cancer live longer](https://gatewaycr.org/about/in-the-news/helping-patients-with-lung-cancer-live-longer/) - Helping patients with lung cancer live longer Every year in the U.S., about 40,000 people get a tough form of lung cancer called NSCLC with a KRAS mutation. Even with the best treatments around, most people with this mutation don’t make it past five years. Dr. Gerber at University of Texas Southwestern Medical Center recently
- [Healing with Hope: The Trial That Changed Maddy’s Future](https://gatewaycr.org/about/in-the-news/healing-with-hope-the-trial-that-changed-maddys-future/) - At 17, Maddy thought the ache in her hip was just a pulled muscle from soccer practice. Instead, she learned it was something far more serious—osteosarcoma, a rare and aggressive bone cancer with a grim prognosis for kids her age. The usual treatment for osteosarcoma isn’t gentle. It’s months of high-dose chemotherapy, surgery that can
- [New Advancements in Treating one of the Deadliest Thyroid Cancers](https://gatewaycr.org/about/in-the-news/new-advancements-in-treating-one-of-the-deadliest-thyroid-cancers/) - New Advancements in Treating one of the Deadliest Thyroid Cancers ASCO: Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer MD Anderson News Release May 31, 2025 A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients with rare BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC) compared with
- [Immunotherapy Is Changing Cancer Treatment Forever](https://gatewaycr.org/about/in-the-news/immunotherapy-is-changing-cancer-treatment-forever/) - Rewiring Hope: T-Cells Take on Brain Cancer Immunotherapy Is Changing Cancer Treatment Forever His brain tumor was a hopeless case. Then an experimental medicine made it melt away. July 15, 2024 – One morning at the end of April 2023, Marcela Maus, a cancer researcher at Mass General in Boston, got a call from her
- [Experts urge study of psilocybin, other psychedelics for cancer-related distress](https://gatewaycr.org/about/in-the-news/experts-urge-study-of-psilocybin-other-psychedelics-for-cancer-related-distress/) - Experts urge study of psilocybin, other psychedelics for cancer-related distress By Jennifer Southall for Healio (Healio, August 17, 2023) The prevalence of distress among women with late-stage gynecologic cancers calls for well-designed studies to assess the safety and efficacy of psychedelics for this patient population, according to authors of a published commentary. Psychedelics — specifically
- [The Dangers of Googling Your Cancer Diagnosis](https://gatewaycr.org/about/in-the-news/the-dangers-of-googling-your-cancer-diagnosis/) - Many people tend to seek health information online. Learn more about the dangers of googling your symptoms and diagnosis.
- [Elevated PSA Level Doesn’t Always Mean Prostate Cancer](https://gatewaycr.org/about/in-the-news/elevated-psa-level-doesnt-always-mean-prostate-cancer/) - While an elevated PSA test may indicate prostate cancer, it could also be due to several other factors. Learn more about what an elevated PSA test could mean.
- [Gateway for Cancer Research to Announce Significant Funding Opportunity at Gateway to Hope Event](https://gatewaycr.org/about/in-the-news/gateway-for-cancer-research-to-announce-significant-funding-opportunity-at-gateway-to-hope-event/) - Gateway for Cancer Research to Announce Significant Funding Opportunity at Gateway to Hope Event May 30, 2019 RECEPTION SHOWCASES NEW PARTNERSHIP TO ADVANCE INNOVATIVE CLINICAL TRIAL RESEARCHCHICAGO, IL – Gateway for Cancer Research (Gateway), a non-profit organization dedicated to funding transformational cancer research, will host “Gateway to Hope,” an annual reception held in conjunction with the American
- [Appendix Cancer Symptoms & Signs: A Comprehensive Guide | GCR](https://gatewaycr.org/about/in-the-news/how-to-recognize-the-signs-and-symptoms-of-appendix-cancer/) - Learn to recognize the signs and symptoms of appendix cancer. Understand its origins, diagnosis methods, and treatment options for better outcomes
- [2019 Young Investigators Award](https://gatewaycr.org/about/in-the-news/2019-young-investigators-award/) - The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology.
- [Arizona Cardinal's Larry Fitzgerald Honored for Leadership in Cancer Advocacy at Gateway for Cancer Research's  4th Annual Vino Con Stelle](https://gatewaycr.org/about/in-the-news/arizona-cardinals-larry-fitzgerald-honored-for-leadership-in-cancer-advocacy-at-gateway-for-cancer-researchs-4th-annual-vino-con-stelle/) - Gateway for Cancer Research celebrated Arizona Cardinals player Larry Fitzgerald with the Leadership in Cancer Advocacy Award at the 4th annual Vino con Stelle.
- [Gateway for Cancer Research and Society for Integrative Oncology join forces](https://gatewaycr.org/about/in-the-news/gateway-for-cancer-research-and-society-for-integrative-oncology-join-forces/) - Gateway for CancerSM announces a scientific collaboration with the Society for Integrative Oncology (SIO) to advance evidence‐based integrative research.
- [Gateway to Oz](https://gatewaycr.org/about/in-the-news/gateway-to-oz/) - All proceeds from “Gateway to OZ” will help support Gateway for Cancer Research Phase I and Phase II trials across cancer types.
- [<strong>Gateway Celebrity Fight Night Returns April 1 with Star-studded Lineup</strong>](https://gatewaycr.org/about/in-the-news/gateway-celebrity-fight-night-returns-april-1-with-star-studded-lineup/) - Gateway Celebrity Fight Night Returns April 1 with Star-studded Lineup FOR IMMEDIATE RELEASEMedia Contact: Tony Fordetforde@kruppnyc.com212-886-6707 Gateway Celebrity Fight Night Returns April 1 with Star-studded Lineup David Foster, Earth, Wind & Fire, Nile Rodgers & CHIC, Taylor Dayne, Thelma Houston, The Sugarhill Gang, Katharine McPhee, and Light Balance to perform at Arizona’s premiere fundraising event100%
- [Gateway For Cancer Research Raised $4.2 Million at its Annual Cures Gala, "Gateway Studio 54"](https://gatewaycr.org/about/in-the-news/gateway-for-cancer-research-raised-4-2-million-at-its-annual-cures-gala-gateway-studio-54/) - Gateway For Cancer Research Raised $4.2 Million at its Annual Cures Gala, "Gateway Studio 54" November 4, 2019 CeeLo Green, SugarHill Gang, Tony Vincent and More Performed Live While Melissa Peterman Emceed Annual Event Benefitting Cancer Clinical Trials and Lifesaving Research SCHAUMBURG, IL – Gateway for Cancer Research, a non-profit organization dedicated to funding transformational cancer research,
- [Celebrity Fight Night Foundation Merges with Gateway for Cancer Research to Deliver a Knockout Blow to Cancer](https://gatewaycr.org/about/in-the-news/celebrity-fight-night-foundation-merges-with-gateway-for-cancer-research-to-deliver-a-knockout-blow-to-cancer/) - Celebrity Fight Night Foundation is merging with Gateway for Cancer Research, a global sponsor of innovative, patient-centric, clinical cancer research.
- [Gateway Celebrity Fight Night-- Arizona's Most Elegant and Exciting Celebrity Red Carpet Charity Event-- Raised More Than $3 Million for Cancer Research in One Night](https://gatewaycr.org/about/in-the-news/elementor-2860/) - Gateway Celebrity Fight Night-- Arizona's Most Elegant and Exciting Celebrity Red Carpet Charity Event-- Raised More Than $3 Million for Cancer Research in One Night PHOENIX, April 4, 2023 /PRNewswire/ — Gateway for Cancer Research—a nonprofit 501c(3) organization committed to funding innovative cancer research that helps people living with cancer to feel better and live longer as we
- [Comprehensive Guide on Cancer Immunotherapy - Gateway CR](https://gatewaycr.org/about/in-the-news/cancer-immunotherapy/) - Dive deep into the world of cancer immunotherapy with our comprehensive guide. Discover FDA-approved treatments, their impact, and breakthroughs.
- [7 Natural Supplements Cancer Patients Should Avoid](https://gatewaycr.org/about/in-the-news/7-natural-supplements-cancer-patients-should-avoid/) - Explore the complex relationship between dietary supplements and cancer care, learn which supplements to avoid, and understand the importance of consulting healthcare professionals for informed decisions.
- [Cancer Awareness Month Calendar](https://gatewaycr.org/about/in-the-news/cancer-awareness-month/) - There are many cancer awareness months for different forms of cancer. They’re important in promoting early diagnosis and raising funds for cancer research.
- [American Lung Association, Gateway for Cancer Research Partner to Develop Personalized Lung Cancer Vaccine](https://gatewaycr.org/about/in-the-news/american-lung-association-gateway-for-cancer-research-partner-to-develop-personalized-lung-cancer-vaccine/) - American Lung Association, Gateway for Cancer Research Partner to Develop Personalized Lung Cancer Vaccine FOR IMMEDIATE RELEASEMegan Foellmfoell@kruppagency.com(203) 516-1694 Organizations provide $678,000 for five-year vaccine trial for small cell lung cancer CHICAGO, May 3, 2023 — Gateway for Cancer Research, a nonprofit organization dedicated to funding transformational early phase cancer clinical trials around the world, today announced a
- [One and a Half Million Grant in Scientific Partnership with Conquer Cancer](https://gatewaycr.org/about/in-the-news/one-and-a-half-million-grant-in-scientific-partnership-with-conquer-cancer/) - $1.5 Million Grant in Scientific Partnership with Conquer Cancer, the ASCO Foundation Will Fund Innovative Immunotherapy Cancer Study at Wilmot Cancer Institute May 30, 2020 CHICAGO, IL – Gateway for Cancer ResearchSM (Gateway), a nonprofit organization dedicated to funding transformational early-phase cancer research, in partnership with Conquer Cancer®, the ASCO Foundation, is pleased to announce the recipient
- [Next Frontiers in Precision Oncology Meet Dr. Laura Agresta](https://gatewaycr.org/about/in-the-news/next-frontiers-in-precision-oncology-meet-dr-laura-agresta/) - Read about how Laura Agresta, MD, will advance her precision oncology use of genetically-informed “smart drugs” and combination therapies.
- [New Decentralized Grants Program Advances Cancer Research in the COVID-19 Era](https://gatewaycr.org/about/in-the-news/new-decentralized-grants-program-advances-cancer-research-in-the-covid-19-era/) - To address this threat to cancer care and research, Gateway quickly focused on one clear goal: to bring cancer clinical trials to the patients’ doorstep.
- [Mobile Technology and Telemedicine](https://gatewaycr.org/about/in-the-news/mobile-technology-and-telemedicine/) - Gateway for CR is launching a new grant program to fund clinical trials leveraging mobile technology and telemedicine to advance cancer science and care.
- [How Moles Turn Into Melanoma](https://gatewaycr.org/about/in-the-news/how-moles-turn-into-melanoma/) - Genetic mutations in a mole can determine if it may progress into cancer. Learn about how to detect melanoma earlier to improve treatment and survival rates.
- [Gateway Discovery Grant to Fund Clinical Cancer Research Addressing Health Disparities](https://gatewaycr.org/about/in-the-news/gateway-discovery-grant-to-fund-clinical-cancer-research-addressing-health-disparities/) - This award will be focused on funding clinical trials with the strong potential to address health disparities within underrepresented patient populations.
- [EORTC 1634-Brain Tumour Group trial in Post-Pubertal Patients with Newly-Diagnosed Medulloblastoma (PersoMed-I) receives support from Gateway for Cancer Research℠](https://gatewaycr.org/about/in-the-news/eortc-1634-brain-tumour-group-trial-in-post-pubertal-patients-with-newly-diagnosed-medulloblastoma-persomed-i-receives-support-from-gateway-for-cancer-research/) - The EORTC 1634-BTG trial provides an opportunity to investigate a medical therapy that can be applied to 70% of adolescent and adults with medulloblastoma.
- [Why Giving to Cancer Research Matters](https://gatewaycr.org/about/in-the-news/why-giving-to-cancer-research-matters/) - Cancer research has yielded successes with even more promising breakthroughs on the near horizon. To get there, researchers rely on a steady stream of funding.

## Categories

- [In the News](https://gatewaycr.org/category/in-the-news/) - Explore cancer news, helpful information, living better with cancer, and the latest news and announcements from Gateway.